[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Zyversa Therapeutics Inc (ZVSA)

Zyversa Therapeutics Inc (ZVSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 786
  • Shares Outstanding, K 7,936
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,950 K
  • EBIT $ -25 M
  • EBITDA $ -25 M
  • 60-Month Beta 0.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.83
  • Most Recent Earnings $-0.22 on 05/13/26
  • Next Earnings Date 09/02/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0774 +27.91%
on 08/19/26
0.1240 -20.16%
on 08/07/26
-0.0020 (-1.98%)
since 07/31/26
3-Month
0.0774 +27.91%
on 08/19/26
0.2050 -51.71%
on 06/04/26
-0.0712 (-41.83%)
since 06/01/26
52-Week
0.0774 +27.91%
on 08/19/26
0.3000 -67.00%
on 01/12/26
-0.0162 (-14.06%)
since 08/29/25

Most Recent Stories

More News
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100...

ZVSA : 0.0990 (unch)
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion. Inflammasome ASC Inhibitor IC 100 is the next evolution...

ZVSA : 0.0990 (unch)
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update    

ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion. Inflammasome ASC Inhibitor IC 100 is a next generation...

ZVSA : 0.0990 (unch)
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

ZyVersa Therapeutics, a biopharma company developing first-in-class drugs for renal and inflammatory diseases, reports 2025 financial results....

ZVSA : 0.0990 (unch)
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and...

ZVSA : 0.0990 (unch)
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator...

ZVSA : 0.0990 (unch)
ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

Type 2 diabetes (T2DM), affecting more than 530 million worldwide, is a metabolic disease often coupled with cardiovascular complications including coronary artery disease, heart failure, and stroke. ...

ZVSA : 0.0990 (unch)
ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

Inflammasome-induced inflammation plays a central role in the development and progression of T2DM and its cardiovascular complications....

ZVSA : 0.0990 (unch)
ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

ZyVersa is developing Cholesterol Efflux Mediator™ VAR 200 to mediate removal of damaging excess cholesterol and other lipids from the kidneys’ filtration system. VAR 200 directly removes lipids from...

ZVSA : 0.0990 (unch)
ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

Lipid alterations in Alport syndrome are linked to impaired ABCA1 lipid efflux and the underlying renal injury processes of lipotoxicity and inflammation....

ZVSA : 0.0990 (unch)

Business Summary

ZyVersa Therapeutics Inc. is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates which address high unmet medical needs in the areas of renal and inflammatory diseases. The company's development pipeline includes phase 2a ready...

See More

Key Turning Points

3rd Resistance Point 0.0990
2nd Resistance Point 0.0990
1st Resistance Point 0.0990
Last Price 0.0990
1st Support Level 0.0990
2nd Support Level 0.0990
3rd Support Level 0.0990

See More

52-Week High 0.3000
Fibonacci 61.8% 0.2150
Fibonacci 50% 0.1887
Fibonacci 38.2% 0.1624
Last Price 0.0990
52-Week Low 0.0774

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.